DekaBank Deutsche Girozentrale
YMAB

DekaBank Deutsche Girozentrale’s Y-mAbs Therapeutics YMAB Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-14,400
Closed -$209K – 1411
2022
Q3 		$209K Hold
14,400
– – ﹤0.01% 1220
2022
Q2 		$210K Hold
14,400
– – ﹤0.01% 1179
2022
Q1 		$172K Buy
14,400
+1,300
+10% +$13.3K ﹤0.01% 1232
2021
Q4 		$221K Buy
13,100
+400
+3% +$8.55K ﹤0.01% 1254
2021
Q3 		$355K Hold
12,700
– – ﹤0.01% 1116
2021
Q2 		$430K Hold
12,700
– – ﹤0.01% 1100
2021
Q1 		$376K Hold
12,700
– – ﹤0.01% 1074
2020
Q4 		$640K Sell
12,700
-600
-5% -$27.8K ﹤0.01% 971
2020
Q3 		$539K Buy
+13,300
New +$529K ﹤0.01% 918

Other funds holding YMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

DekaBank Deutsche Girozentrale's YMAB Position: Q4 2022 in Review

DekaBank Deutsche Girozentrale sold out of Y-mAbs Therapeutics (YMAB) in Q4 2022, closing a stake of 14,400 shares — an estimated $209K sold.

DekaBank Deutsche Girozentrale first reported a position in YMAB in Q3 2020 and held it in 9 quarters. The position peaked at $640K in Q4 2020. 91 funds tracked by Wall St. Rank hold YMAB as of Q4 2022.

  • DekaBank Deutsche Girozentrale reported no remaining Y-mAbs Therapeutics position as of Q4 2022 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 14,400 Y-mAbs Therapeutics shares in Q4 2022, an estimated $209K.
  • DekaBank Deutsche Girozentrale first reported a position in Y-mAbs Therapeutics in Q3 2020 and held it in 9 quarters.
  • DekaBank Deutsche Girozentrale's Y-mAbs Therapeutics position peaked at $640K in Q4 2020.
  • 91 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2022.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q4 2022, filed 1 Feb 2023.